Stifel rated the Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s stock as a Hold in a research note published on Thursday, December 6th, 2018. Other Wall Street experts have also recently posted reports on these shares. ROTH Capital gave the stock a Buy rating, while setting a price target at $20 in a research note from Thursday, February 8th, 2018. H.C. Wainwright posted a $17 price target for Conatus Pharmaceuticals Inc. stock and rated the stock as a Buy in a research note dated Thursday, November 2nd, 2017.
At the moment, there are a total of 5 analysts who cover Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock. Among that group, 1 of them gave BUY ratings, 3 of them rated the stock as OUTPERFORM, 1 recommended it as HOLD, 0 set the rating at UNDERPERFORM and 0 rated it as a SELL. Looking at the big picture from the data above, the average analyst rating for Conatus Pharmaceuticals Inc. is 2.00.
The company, which is valued at $87.95M, last published its earnings results on Friday, 03/08/2019 for the quarter that ended in Dec-18. The business posted revenue of $7.41 million for the three-month period, below -$1.22 million, compared to analysts’ forecasts of $8.63 million with a surprise factor of 14.14%.
At times, the stock market can get highly confusing – even for some of the most experienced traders. Even when the result is what you had expected, the market might suddenly decide to make an opposing movement. This can spark a great deal of doubt and second-guessing. Keeping tabs on historical price performance, as well as both long-term and short-term trends, can be very useful. Over the past 7 days, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock has increased in price by 41.79%. Looking backwards over the past quarter, these shares have gained 75.93%. Turning to look at the last 6 months, this stock has dropped 39.75% to its price. Since the beginning of the calendar year, this stock has moved down by 58.82%.
Now let’s examine some potential support and resistance levels for this particular stock. Following a recent spotcheck, the public organization Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has been observed as trading -5.63% away from its 90-day high price. Taking a look at the other side of things, this stock has been trading +147.83% away from its 90-day low. Moving to a broader perspective, this stock has recently been trading -57.68% away from its 52-week high and +147.83% away from its 52-week low price.
Regular shareholders want to find out how lucrative the capital that they’ve invested into a business has become. This particular public company has given a ROE of -81.30% . The lower the ROE, the worse a business is at generating profits. The Return on Assets (ROA) ratio, on the other hand, shows how profitable an organization is relative to its total assets owned. This company’s ROA is currently -25.20%. A business that is good at managing their assets will show a higher return, whereas if they poorly manage their assets the return will be low. This public organizations Return on Investment (ROI) is -44.40% . A percentage that’s positive means that profits exceed costs – so analysts consider the investment as a net gain. A negative result, however, indicates that costs outweigh profits – wo analysts would view it as a net loss.
Now let’s look at this public company’s trading volatility. Its 1-Week Volatility currently stands at 17.08%, while its Month Volatility is 9.41%. This stock’s ATR (Average True Range) is currently 0.22, and its beta factor is currently 3.34. Volatility demonstrates how much the stock will dive or rise if the wider market suffers or surges. A stock that has a beta score higher than 1 means that volatility is high, while less than 1 means that volatility is low.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock slipped -$0.04 lower during the regular trading session on Thursday, hitting $2.85. This organization’s stock showed a trading volume of 1.86 million shares, compared to its average daily volume of 732.61K shares.